share_log

港股异动 | 东阳光长江药业(01558)复牌高开逾6% 广东东阳光药业正考虑以换股方式吸收合并公司

Changes in Hong Kong stocks | Dongyangguang Changjiang Pharmaceutical (01558) resumed trading and opened more than 6%. Guangdong Dongyangguang Pharmaceutical is considering absorbing and merging companies through a share exchange

Zhitong Finance ·  Mar 10 21:24

Dongyangguang Changjiang Pharmaceutical (01558) resumed trading more than 6%. As of press release, it rose 6.58% to HK$11.98, with a turnover of HK$3.3832 million.

The Zhitong Finance App learned that Dongyang Changjiang Pharmaceutical (01558) resumed trading more than 6%. As of press release, it had risen 6.58% to HK$11.98, with a turnover of HK$3.3832 million.

According to the news, Dongyangguang Changjiang Pharmaceutical announced that its direct shareholder Hong Kong Dongyangyang transferred 25.71% of its shares to Guangdong Dongyangyang Pharmaceutical, with a total consideration of HK$2,067 billion. Compared with the price of HK$9.14 per share, this is an 18.68% discount from the closing price before the suspension of trading.

Furthermore, the company learned that the parent company Guangdong Dongyangguang Pharmaceutical is considering absorbing and merging the company through a share exchange, and will use the new H shares listed on the main board of the Stock Exchange in the form of an introduction as a cancellation price. Once the possible merger is completed, the company's listing status on the Stock Exchange will be cancelled. The possible merger and possible listing are still in the preliminary stages, and it is difficult to determine whether they will proceed.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment